EOCN today
$1.78-$0.04 (-1.98%)close Nov 20, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourStrong Bearish
15 minStrong Bearish
5 minConsolidating
Daily trend turns up above $3.48
Key levels
Resistance$2.98
Resistance$2.30
Latest news & SEC filings
ProductEocene and Barcode Nanotech advance tumor-targeting Aramchol formulation development
ProductEocene: Galmed and Barcode Nanotech make preclinical nanoparticle Aramchol for liver, GI tumor fibrosis
ProductEocene Ltd. launches CG-100 commercially in Greece and Cyprus
All EOCN news →About Galmed Pharmaceuticals
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company based in Israel. It is developing Aramchol, an oral drug candidate, initially for NASH and liver fibrosis and now also for oncological indications. The company is also exploring cardiometabolic programs and has no approved products or in-house manufacturing, relying on third parties.
Based on the company's 20-F filed Mar 31, 2026.
·
EOCN (EOCN)
What Is the Price Target for EOCN?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is EOCN a Buy or Sell Right Now?
Test your own strategy on EOCN
Describe your strategy in plain words, then scan, alert, backtest and paper trade it on EOCN with SEPT’s own market data.
Start Free Trial →Is EOCN Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
5
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with EOCN?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See Smart Money Data →EOCN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for EOCN
PREVIEWRecent off-exchange (dark pool) prints for EOCN: size, dollar value and side. One of the data views on SEPT, alongside its own pressure bars, swings, volume spike levels and key levels.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:49:34 | $1.80 | 2,250 | $$4K | BUY |
| 19:11:52 | $1.85 | 2,000 | $$4K | BUY |
| 18:29:20 | $1.95 | 1,010 | $$2K | BUY |
| 18:15:55 | $1.91 | 1,030 | $$2K | SELL |
| 17:43:32 | $1.90 | 1,139 | $$2K | BUY |
5 dark pool trades shown · $$14K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for EOCN (EOCN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
Your strategy, tested before real money.
Describe your strategy in plain words. SEPT scans, alerts, backtests and paper trades it on its own market data. SEPT provides tools only and does not tell you what to buy or sell.
Try SEPT Free for 7 Days →EOCN — frequently asked questions
What is EOCN stock price today?
EOCN (EOCN) is at $1.78, down 1.98% (-$0.04) at the Nov 20, 2026 close.
Why is EOCN stock moving today?
Latest EOCN news — Nov 17, 2026: Eocene and Barcode Nanotech advance tumor-targeting Aramchol formulation development · Nov 16, 2026: Eocene: Galmed and Barcode Nanotech make preclinical nanoparticle Aramchol for liver, GI tumor fibrosis
Did EOCN beat earnings?
EOCN last reported on Sep 2, 2026: EPS -$2.86 vs -$3.12 expected — a beat of 8.3%.
What are EOCN support and resistance levels?
Resistance: $2.30, $2.98, $3.48.
What are insiders doing with EOCN?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on EOCN?
Nov 17, 2026: Eocene and Barcode Nanotech advance tumor-targeting Aramchol formulation development · Nov 16, 2026: Eocene: Galmed and Barcode Nanotech make preclinical nanoparticle Aramchol for liver, GI tumor fibrosis · Nov 11, 2026: Eocene Ltd. launches CG-100 commercially in Greece and Cyprus